tirzepatide and vision macular degeneration NEJM Editorial Fellow Katerina Lin, MD, unpacks the science behind a study on Researchers Find Small Increased Risk

But they still make for an interesting innovation worth your read

This approach ensures that each patients unique health requirements are addressed, providing optimal support for their specific conditions and health goals

While Medicare still does not cover semaglutide solely for obesity, it may cover the Wegovy Pill or injection if you have established heart disease (to reduce cardiovascular risk) or if your state Medicaid plan participates in the new 2026 federal pilot programs

Individual variation in drug response is significantbiological differences in GLP-1 receptor expression and function may contribute to why some patients naturally respond more robustly than others, though this is not routinely assessed in clinical practice